Gp. Aithal et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, LANCET, 353(9154), 1999, pp. 717-719
Citations number
17
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background The cytochrome P450 CYP2C9 is responsible for the metabolism of
S-warfarin. Two known allelic variants CYP2C9*2 and CYP2C9*3 differ from th
e wild type CYP2C9*1 by a single aminoacid substitution in each case. The a
llelic variants are associated with impaired hydroxylation of S-warfarin in
in-vitro expression systems. We have studied the effect of CYP2C9 polymorp
hism on the in-vivo warfarin dose requirement.
Methods Patients with a daily warfarin dose requirement of 1.5 mg or less (
low-dose group, n=36), randomly selected patients with a wide range of dose
requirements from an anticoagulant clinic in north-east England (clinic co
ntrol group, n=52), and 100 healthy controls from the community in the same
region were studied. Genotyping for the CYP2C9*2 and CYP2C9*3 alleles was
done by PCR analysis. Case notes were reviewed to assess the difficulties e
ncountered during the induction of warfarin therapy and bleeding complicati
ons in the low-dose and clinic control groups.
Findings The odds ratio for individuals with a low warfarin dose requiremen
t having one or more CYP2C9 variant alleles compared with the normal popula
tion was 6.21 (95% CI 2.48-15.6). Patients in the low-dose group were more
likely to have difficulties at the time of induction of warfarin therapy (5
.97 [2.26-15.82]) and have increased risk of major bleeding complications (
rate ratio 3.68 [1.43-9.50]) when compared with randomly selected clinic co
ntrols.
Interpretation We have shown that there is a strong association between CYP
2C9 variant alleles and low warfarin dose requirement. CYP2C9 genotyping ma
y identify a subgroup of patients who have difficulty at induction of warfa
rin therapy and are potentially at a higher risk of bleeding complications.